| Bioactivity | Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis[1]. | ||||||||||||
| In Vivo | Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP[1].. Animal Model: | ||||||||||||
| Name | Oxethazaine | ||||||||||||
| CAS | 126-27-2 | ||||||||||||
| Formula | C28H41N3O3 | ||||||||||||
| Molar Mass | 467.64 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. SEIFTER J, ET AL. Oxethazaine and related congeners: a series of highly potent local anesthetics. Proc Soc Exp Biol Med. 1962 Mar;109:664-8. [2]. Soo-Yeun Lee, et al. The abuse potential of oxethazaine: Effects of oxethazaine on drug-seeking behavior and analysis of its metabolites in plasma and hair in animal models. Pharmacology, Biochemistry and Behavior |
Oxethazaine
CAS: 126-27-2 F: C28H41N3O3 W: 467.64
Oxethazaine (Oxetacaine), a precursor of phentermine acidic,is an acid-resistent and orally active analgesic agent. Oxe
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.